Development pipeline

Indatuximab Ravtansine (BT-062)

Indatuximab Ravtansine (BT-062) is an immune conjugate, consisting of a monoclonal antibody to which a highly effective cytotoxic maytansien derivative (DM4) is coupled. The immune conjugate technology, developed by ImmunoGen, Inc, is used for toxin conjugation. The antibody is directed against the CD138 receptor, which is over-expressed on multiple myeloma cells and on other cells of various types of cancer: solid tumors.

After the conjugate is absorbed into the target cell, DM4 is released and exerts its cytotoxic activity so that the tumor cell is killed. This combination of high effectiveness and specificity with low systemic toxicity distinguishes BT-062 from most therapies currently used in oncology.

Press releases

Biotest AG: Annual general meeting approves payout of d...

30.08.2017, News

Biotest AG: Annual general meeting approves payout of dividend - Dividend payout of EUR 0.05 per ordinary share and EUR 0.07 per preference share Dreieich/ Frankfurt a. M., 30 August 2017. At the ... [More]

DGAP-AFR: Biotest AG: Preliminary announcement of the p...

23.08.2017, AFR

Biotest AG hereby announces that the following financial reports shall be disclosed for the business year 2017: Report: Quarterly financial report within the 2nd half-year (Q3) Date of disclosure ... [More]

Biotest reported sales of EUR 247.1 million in the firs...

14.08.2017, News

Biotest reported sales of EUR 247.1 million in the first half of 2017 - Successful building inspection of the new building at Dreieich - Closing of the Public Takeover Offer is subject to the ... [More]

Biotest takes over Cara Plasma s.r.o. with one plasma c...

19.07.2017, News

Biotest takes over Cara Plasma s.r.o. with one plasma collection centre in the Czech Republic - Long-term plasma supplier Cara Plasma was taken over by Biotest - Biotest has now 16 plasma ... [More]

Biotest reaches 2nd milestone in Biotest Next Level exp...

22.06.2017, News

Biotest reaches 2nd milestone in Biotest Next Level expansion project - Authorities grant building approval - Relocation activities of laboratories and offices for production start in June ... [More]

Biotest AG shareholders accept voluntary public tender ...

14.06.2017, News

Biotest AG shareholders accept voluntary public tender offer by CREAT Group Dreieich, 14 June, 2017. The shareholders of Biotest AG have accepted the voluntary public tender offer by Tiancheng ... [More]

Release according to Article 26, Section 1 of the WpHG ...

12.06.2017, PVR

Notification of Major Holdings 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification Acquisition/disposal of shares ... [More]

Biotest sold US therapy business to ADMA Biologics, Inc...

07.06.2017, News

Biotest sold US therapy business to ADMA Biologics, Inc. - Biotest receives 50% minus one share of ADMA - Biotest receives also distribution rights of specified current product and a right of ... [More]

Release according to Article 26, Section 1 of the WpHG ...

06.06.2017, PVR

Notification of Major Holdings 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification Acquisition/disposal of ... [More]

Release according to Article 26, Section 1 of the WpHG ...

01.06.2017, PVR

Notification of Major Holdings 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification Acquisition/disposal of ... [More]

Release according to Article 26, Section 1 of the WpHG ...

01.06.2017, PVR

Notification of Major Holdings 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification Acquisition/disposal of ... [More]

Joint reasoned statement of Biotest AG - Management Boa...

01.06.2017, News

Joint reasoned statement of Biotest AG - Management Board and Supervisory Board recommend to accept tender offer of CREAT Group Dreieich, 1 June, 2017. Today, the Management Board and Supervisory ... [More]

Release according to Article 26, Section 1 of the WpHG ...

24.05.2017, PVR

Notification of Major Holdings 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification Acquisition/disposal of ... [More]

Publication of the offer document on the voluntary publ...

18.05.2017, News

Publication of the offer document on the voluntary public tender for Biotest AG by CREAT Group - Offer document reaffirms the offer announced on April 7, 2017 - The Management Board and the ... [More]

DGAP-AFR: Biotest AG: Preliminary announcement of the p...

17.05.2017, AFR

Biotest AG hereby announces that the following financial reports shall be disclosed : Report: Financial report (half-year/Q2) Date of disclosure / German: August 14, 2017 Date of disclosure / ... [More]

Biotest AG opens seventh plasma collection centre in Hu...

16.05.2017, News

Biotest AG opens seventh plasma collection centre in Hungary - 15 plasma collection centres in Europe and - 22 in the US to ensure long-term plasma supply Dreieich, 16 May 2017. Biotest ... [More]

Biotest reports revenue of EUR 110 million in the first...

10.05.2017, News

Biotest reports revenues of EUR 110.5 million in the first quarter 2017 Dreieich, 10 May 2017. In the first quarter of 2017, the Biotest Group generated sales of EUR 110.5 million, after EUR 133.6 ... [More]

Correction of a release from 07.04.2017, 15:23 CET/CEST...

04.05.2017, PVR

Correction of a notification of Major Holding published on 07.04.2017 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for ... [More]

Release according to Article 26, Section 1 of the WpHG ...

28.04.2017, PVR

Notification of Major Holdings 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of ... [More]

Voluntary recall of human albumin

26.04.2017, News

Biotest: Voluntary recall of human albumin - Already quarantined batches of human albumin are recalled - Consequences of the one-time effect on Sales and EBIT are currently being evaluated - As ... [More]

Conference dates

03.12.2016 – 06.12.2016 | San Diego

Publications

preview

ASH 2014 American Society of Hematology (06.12.2014 – 09.12.2014, San Francisco)
PDF, 398.98 kB
[ Download ]

preview

World ADC Weltkongress Antibody Drug Conjugates (26.10.2014 – 29.10.2014, San Diego)
PDF, 834.64 kB
[ Download ]

preview

ASH 2013 American Society of Hematology (06.12.2013 - 10.12.2013, New Orleans)
PDF, 41.61 kB
[ Download ]

preview

ASH 2012 American Society of Hematology, 8. - 11. Dez. 2012, Atlanta (USA)
PDF, 387.58 kB
[ Download ]

preview

Tassone et al.: Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood. 2004 Dec 1;104(12):3688-96
[ Link ]

preview

Ikeda et al.: The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo.Clin Cancer Res. 2009, Jun 15;15(12):4028-37
[ Link ]

Clinical trials

Title

Indication

Status

 
Indatuximab Ravtansine (Study 983) Multiple myeloma Study ongoing

BT062 in Combination With Lenalidomide/Dexamethasone in Patients With Multiple Myeloma

Link clinicaltrials.gov
 
Indatuximab Ravtansine (Study 975) Multiple myeloma Study completed

Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma

 
Indatuximab Ravtansine (Study 969) Multiple myeloma Study completed

Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma

 
Indatuximab Ravtansine* (Study 989) Solid tumors Study ongoing

An open-label, twostage Phase I/IIa dose escalation study of BT062 in metastatic triple receptor-negative breast cancer and in metastatic transitional cell carcinoma of the urinary bladder

Link clinicaltrialsregister.eu